Literature DB >> 7928808

Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria.

P C Fuchs1, A L Barry, M A Pfaller.   

Abstract

The antibacterial activity of PD 131628 was compared with that of ciprofloxacin against 401 clinical isolates. The two drugs had comparable MICs for most Gram-negative species. PD 131628 was two to eight times more active against Gram-positive species and against Xanthomonas maltophilia. Both drugs were bactericidal, Among Gram-positive isolates, resistant mutants were not detected in vitro. Among Gram-negative bacilli, spontaneously occurring mutants resistant to PD 131628 were readily demonstrated more frequently than for ciprofloxacin. Resistance to PD 131628 was more readily induced by serially transferring the Gram-negative species, and resistant organisms emerged more rapidly on prolonged incubation in time-kill studies. Correlating the PD 131628 5 micrograms disc diffusion zone diameters with PD 131628 MICs, the following breakpoints are tentatively proposed: susceptible, MIC < or = 1 mg/L or zone > or = 19 mm; intermediate, MIC 2.0 mg/L or zones 16-18 mm; and resistant, MIC > or = 4.0 mg/L or zones < or = 15 mm.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7928808     DOI: 10.1093/jac/33.6.1147

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.

Authors:  A L Barry; P C Fuchs; S D Allen; F C Tenover; J H Jorgensen; L B Reller
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

Review 2.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 3.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.